Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 9/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 9/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097508 | 0.91 | TP53 (0.53) | DRD2TBXA2RTP53MAPTPOLB | |
| SCHEMBL2161533 | 0.88 | KDM4E (0.68) | KDM4ETP53MAPTPOLBLMNA | |
| SCHEMBL3149852 | 0.82 | TBXA2R (0.48) | KDM4ETBXA2RTP53MAPTPOLB | |
| SCHEMBL23997462 | 0.81 | DRD2 (0.75) | DRD2TBXA2RTP53MAPTLMNA | |
| SCHEMBL30336823 | 0.81 | DRD2 (0.75) | DRD2TBXA2RTP53MAPTLMNA | |
| SCHEMBL8025911 | 0.80 | KDM4E (0.70) | KDM4EDRD2TBXA2RPPARG | |
| SCHEMBL22955656 | 0.80 | DRD2 (0.51) | KDM4EDRD2TBXA2RTP53MAPT | |
| SCHEMBL4532827 | 0.77 | PPARG (0.68) | KDM4EDRD2TBXA2RMAPTPPARG | |
| SCHEMBL2162428 | 0.77 | AGTR1 (0.56) | KDM4ETBXA2RTP53LMNAPPARG | |
| SCHEMBL19987318 | 0.77 | KDM4E (0.68) | KDM4EMAPTPPARGCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163774-B2 | Antidiabetic agents; 2-(amino-substituted piperidin-1-yl)benzimidazoles; N-(4-Chlorobenzyl)-2-(3-aminopiperidin-1-yl)-1-(4-fluorobenzyl)-1H-benzimidazole-6-carboxamide hydrochloride for example; use in combination with other antidiabetic, antilipemic agents | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| US-20080090868-A1 | AMIDE-SUBSTITUTED 8 N BENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090868-A1 | AMIDE-SUBSTITUTED 8 N BENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | DPP8, GPR119, ABAT | KDM4E 753/4885DRD2 2097/4885TBXA2R 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.